top

  Info

  • Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.

  Info

  • Utilizzare questo link per rimuovere la selezione effettuata.
Advances in Cancer Treatment : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares
Advances in Cancer Treatment : From Systemic Chemotherapy to Targeted Therapy / / by Iago Dillion Lima Cavalcanti, José Cleberson Santos Soares
Autore Cavalcanti Iago Dillion Lima
Edizione [1st ed. 2021.]
Pubbl/distr/stampa Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021
Descrizione fisica 1 online resource (VIII, 109 p. 27 illus., 25 illus. in color.)
Disciplina 616.994
Soggetto topico Oncology
Internal medicine
Pharmacy
Cancer—Treatment
Tumor markers
Cancer
Nanomedicine
Internal Medicine
Cancer Therapy
Tumour Biomarkers
Cancer Nanotechnology
Oncologia
Terapèutica
Fisiologia patològica
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 3-030-68334-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Introduction -- Cancer: concepts and epidemiology -- A brief history of cancer -- What is Cancer? -- Cancer Epidemiology -- Cancer development and immunology -- Cell cycle -- Cell cycle control: the function of cyclins -- Cancer triggering agents -- Proto-oncogenes -- Tumor suppressor genes -- Development of tumor mass -- Cancer Immunology -- Discovery of tumor markers -- Cancer diagnosis -- Impact of the discovery of tumor markers -- Main tumor markers for cancer diagnosis -- Alpha-fetoprotein (AFP) -- Human Chorionic Gonadotropin (β-HCG) -- Mucin-like cancer-associated antigen (MCA) -- CA 15.3 -- Carcinoembryonic antigen (CEA) -- Bladder tumor antigen (BTA) -- Telomerase -- Nuclear matrix protein (NMP 22) -- Cyfra 21.1 -- Prostatic acid phosphatase (PAP) -- Prostate-specific antigen (PSA) -- CA 125 -- CA 19.9 -- p53 -- CA 72.4 -- K-ras -- HER2 -- Cancer staging -- Conventional cancer treatment -- Therapeutic modalities of cancer -- Surgery -- Radiotherapy -- Antineoplastic chemotherapy -- Classification of antineoplastic agents by cycle -- Specific cycle antineoplastics -- Nonspecific antineoplastic agents -- Classification of antineoplastic agents by chemical structure and function -- Alkylating agents -- Antimetabolites -- Plant-derived antineoplastics -- Antitumor antibiotics -- Chemotherapy toxicity -- Hematological toxicity -- Liver toxicity -- Cardiac toxicity -- Anthracyclines -- Fluoropyrimidine -- Taxanes -- Pulmonary toxicity -- Neurological toxicity -- Renal toxicity -- Gastrointestinal toxicity -- Metabolic changes -- Targeted therapies in cancer treatment -- Overexpressed receptors on tumor cells -- Immunotherapy -- Monoclonal antibodies -- Types of monoclonal antibodies -- Side effects of monoclonal antibodies -- Checkpoint Inhibitors -- Side effects of checkpoint inhibitors -- Cancer Vaccines -- Vaccines in cancer prevention -- Vaccines for the treatment of cancer -- Non-specific immunotherapies -- Tyrosine kinase inhibitors -- Imatinib -- Gefitinib -- Erlotinib -- Sorafenib -- Dasatinib -- Nilotinib -- Lapatinib -- Adverse events of tyrosine kinase inhibitors -- Conventional chemotherapy vs. targeted therapy -- Differences between conventional chemotherapy and targeted therapy -- Risks and benefits of conventional chemotherapy compared to targeted therapy -- Eligibility criteria for the indication of the targeted therapy -- Side effects of targeted therapy -- Can targeted therapy replace conventional chemotherapy? -- Targeted therapy associated with conventional chemotherapy -- Pharmaceutical nanotechnology applied to cancer -- Pharmaceutical nanotechnology -- Classification of nanosystems -- Liposomes -- Micelles -- Polymeric nanoparticles -- Solid lipid nanoparticles -- Magnetic nanoparticles -- Metal nanoparticles -- Main functions of nanosystems in cancer -- Pharmaceutical nanotechnology in cancer diagnosis -- Pharmaceutical nanotechnology for cancer treatment.
Record Nr. UNINA-9910484989203321
Cavalcanti Iago Dillion Lima  
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Advances in nanomaterials-based cell biology research / / Yunfeng Lin, Ronghui Zhou, editors
Advances in nanomaterials-based cell biology research / / Yunfeng Lin, Ronghui Zhou, editors
Pubbl/distr/stampa Singapore : , : Springer, , [2021]
Descrizione fisica 1 online resource (227 pages)
Disciplina 610.284
Soggetto topico Nanostructured materials - Health aspects
Nanomedicine
Stem cells
Cèl·lules mare
Materials nanoestructurats
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 981-16-2666-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Contents -- About the Authors -- Chapter 1: Nanomaterials and Stem Cells for Bone Tissue Engineering -- 1.1 Introduction -- 1.2 Stem Cell Types Applied to Nanomaterial-Based Bone Regeneration -- 1.2.1 Mesenchymal Stem Cells (MSCs) -- 1.2.1.1 Bone Marrow Stromal Cells (BMSCs) -- 1.2.1.2 Adipose-Derived Stem Cells (ASCs) -- 1.2.1.3 Dental Pulp Stem Cells (DPSCs) -- 1.2.2 Other Types of Adult Stem Cells -- 1.3 Nanomaterials Applied to Stem Cell Osteogenic Differentiation -- 1.3.1 Polymeric Nanomaterials -- 1.3.2 Metal-Based Nanomaterials -- 1.3.3 Silica-Based Nanomaterials -- 1.3.4 Carbon-Based Nanomaterials -- 1.3.5 Nucleic Acid-Based Nanomaterials -- 1.3.6 Hydroxyapatite -- 1.4 Properties of Nanomaterials Affecting Osteogenic Differentiation and Bone Formation -- 1.4.1 Mechanical Properties -- 1.4.2 Porosity -- 1.4.3 Hydrophilicity -- 1.4.4 Biodegradability -- 1.4.5 Biocompatibility -- 1.5 Nanostructures and Scaffolds Applied to Bone Tissue Engineering -- 1.5.1 Nanopatterns -- 1.5.2 Microspheres/Nanospheres -- 1.5.3 Nanotubes -- 1.5.4 Nanofibers -- 1.5.5 Nanocomposites -- 1.6 Growth Factors and Molecular Pathways Involved in Osteogenic Differentiation and Bone Tissue Engineering -- 1.6.1 Bone Morphogenetic Protein (BMP) -- 1.6.2 Vascular Endothelial Growth Factor (VEGF) -- 1.6.3 Basic Fibroblast Growth Factor (bFGF) -- 1.6.4 Insulin-like Growth Factor-1 (IGF-1) -- 1.6.5 Other Growth Factors Related to Bone Regeneration -- References -- Chapter 2: The Application of Nanomaterial in Skeletal Muscle Regeneration -- 2.1 Introduction -- 2.2 The Research Progress of Nanoscaffold Materials in Skeletal Muscle Regeneration -- 2.2.1 The Research Progress of Nanofiber Scaffold in Skeletal Muscle Regeneration -- 2.2.1.1 Electrospinning Research Progress in Preparation of Nanofibers.
2.2.1.2 The Research Progress of Physical Cues of Nanofibers on Myogenesis -- 2.2.1.3 Biochemical Cues of Nanofibers on Myogenesis -- 2.2.1.4 The Research Progress of Electrical Conductivity of Nanofibers on Myogenesis -- 2.2.1.5 The Research Progress of PCL Scaffolds for Muscle Regeneration -- 2.2.1.6 Other Nanofiber Scaffold Research Progress for Muscle Regeneration -- 2.2.2 The Research Progress of Nanohydrogels in Skeletal Muscle Regeneration -- 2.2.3 The Research Progress of Nanofilm in Skeletal Muscle Regeneration -- 2.2.4 The Research Progress of Nanocomposite Materials in Skeletal Muscle Regeneration -- 2.2.5 Other Nanomaterial Research Progress in Skeletal Muscle Regeneration -- 2.3 The Research Progress of Nanoparticles in Skeletal Muscle Regeneration -- 2.3.1 The Research Progress of Au Nanoparticles in Myogenesis -- 2.3.2 The Research Progress of Nanotubes and Nanorods in Myogenesis -- 2.3.3 The Research Progress of Other Nanoparticles in Myogenesis -- 2.3.4 The Research Progress of Composite Nanoparticles in Myogenesis -- 2.4 Conclusion -- References -- Chapter 3: Application of Nanomaterials in Neurodegenerative Diseases -- 3.1 Introduction -- 3.2 BBB -- 3.3 Nanomaterials -- 3.3.1 Size -- 3.3.2 Shape -- 3.3.3 Charge -- 3.3.4 Delivery Methods -- 3.4 NDD -- 3.4.1 AD -- 3.4.2 PD -- 3.4.3 HD -- 3.4.4 Other -- 3.5 Conclusion -- References -- Chapter 4: Application of Nano Drug Delivery Systems in Inhibition of Tumors and Cancer Stem Cells -- 4.1 Introduction -- 4.2 Cancer Stem Cell -- 4.2.1 Cell Cycle Arrest -- 4.2.2 Drug Efflux -- 4.2.3 DNA Damage Tolerance and DNA Damage Repair -- 4.2.4 Epithelial Mesenchymal Transformation (EMT) -- 4.2.5 Tumor Microenvironment -- 4.3 Nano Drug Delivery Systems -- 4.3.1 Strengthen Drug Stability -- 4.3.2 Enhance Drug Targeting -- 4.3.3 Better Degradability -- 4.3.4 Increase Bioavailability of Drugs.
4.4 Liposomes -- 4.4.1 Overcoming the Quick Elimination by MPS -- 4.4.2 Constructing Active Targeting Liposomes -- 4.4.3 Realizing Triggered Release of Drug -- 4.4.4 Constructing Multifunctional Liposomes -- 4.5 Polymeric Micelles -- 4.5.1 Passive Targeting and Active Targeting Polymeric Micelles -- 4.5.2 Drug Co-delivery Systems -- 4.5.3 Environmentally Responsive Polymeric Micelles -- 4.6 Conclusion -- References -- Chapter 5: The Application and Problems of Tetrahedral Framework Nucleic Acids as a Drug Carrier in Biomedicine Fields -- 5.1 Introduction -- 5.2 DNA Nanostructures -- 5.2.1 The Concept of DNA Nanostructures -- 5.2.2 The Development of DNA Nanostructures -- 5.3 Tetrahedral Framework Nucleic Acids -- 5.3.1 Self-assembly -- 5.3.2 The Physical, Chemical, and Biological Characteristics -- 5.3.2.1 The Nanoscale and Editable -- 5.3.2.2 The Ability to Enter Cells -- 5.3.2.3 Biocompatibility and Biodegradability -- 5.3.2.4 High Chemical Reactivity and Multiple Modification Sites -- 5.3.3 The Application of tFNAs as a Drug Carrier in Biomedicine Fields -- 5.3.3.1 Transport Small-Molecule Drugs for Cancer Therapy -- 5.3.3.2 Transport Functional Nucleic Acids -- Antisense Oligodeoxynucleotide -- Antisense Peptide Nucleic Acid -- Aptamer -- siRNA -- Num, Dpt. -- 5.3.3.3 Transport Peptides and Proteins -- 5.3.3.4 Transport Multiple Drug Molecules -- 5.3.4 The Current Problems of tFNAs as a Drug Carrier in Biomedicine Fields We Faced -- 5.3.4.1 Improves the Stability of DNA Tetrahedron In Vivo -- 5.3.4.2 Improves the Cell Uptake Efficiency of DNA Tetrahedron -- 5.3.4.3 Improve the Synthetic Yield and Reduce the Synthesis Cost of DNA Tetrahedron -- 5.4 Conclusion -- References -- Chapter 6: Research Progress on Antibacterial Application with Nucleic Acid and Nucleic Acid Materials -- 6.1 Introduction -- 6.2 Nucleic Acid Aptamer.
6.3 Antisense Oligonucleotide (ASODN) and Antisense Peptide Nucleic Acid (PNA) -- 6.4 Combined Application of DNA Nanomaterials and Antisense Technology -- 6.5 Combination of DNA Nanostructures and Antibiotics -- 6.6 Combined Application of DNA Nanostructure and Metal Nanoparticles -- 6.7 Combined Application of DNA Nanostructure and Antimicrobial Peptide (AMP) -- 6.8 Antimicrobial Studies of Some Other Nucleic Acid or Analogues -- 6.9 Conclusion -- References -- Chapter 7: The Application of DNA Nanostructures in Vaccine Technology -- 7.1 Introduction -- 7.2 DNA Nanostructures -- 7.2.1 DNA Tetrahedron -- 7.2.2 DNA Nanotubes -- 7.2.3 DNA Hydrogel -- 7.2.4 DNA Nanoflower -- 7.2.5 DNA Dendrimer -- 7.3 Challenge and Prospect -- References.
Record Nr. UNINA-9910495246303321
Singapore : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Cancer nanotheranostics . Volume 1 / / Muthupandian Saravanan, Hamed Barabadi, editors
Cancer nanotheranostics . Volume 1 / / Muthupandian Saravanan, Hamed Barabadi, editors
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (362 pages) : illustrations
Disciplina 616.99406
Collana Nanotechnology in the Life Sciences
Soggetto topico Cancer - Treatment - Technological innovations
Nanomedicine
Theranostic Nanomedicine
Neoplasms - therapy
Càncer
Nanomedicina
Oncologia
Innovacions tecnològiques
Soggetto genere / forma Llibres electrònics
ISBN 3-030-74330-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910502986403321
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Emerging trends in nanomedicine / / Sanjay Singh, editor
Emerging trends in nanomedicine / / Sanjay Singh, editor
Pubbl/distr/stampa Singapore : , : Springer, , [2021]
Descrizione fisica 1 online resource (249 pages)
Disciplina 610.28
Soggetto topico Nanomedicine
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 981-15-9920-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910485006703321
Singapore : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Integrated omics approaches to infectious diseases / / Saif Hameed and Zeeshan Fatima (editors)
Integrated omics approaches to infectious diseases / / Saif Hameed and Zeeshan Fatima (editors)
Pubbl/distr/stampa Gateway East, Singapore : , : Springer, , [2021]
Descrizione fisica 1 online resource (538 pages)
Disciplina 616.9
Soggetto topico Parasitology
Communicable diseases - Etiology
Malalties infeccioses
Etiologia
Biologia molecular
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 981-16-0691-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910495232703321
Gateway East, Singapore : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors)
Nanomedicine for cancer diagnosis and therapy / / Arshi Malik, Sarah Afaq and Mohammed Tarique (editors)
Pubbl/distr/stampa Gateway East, Singapore : , : Springer, , [2021]
Descrizione fisica 1 online resource (251 pages)
Disciplina 616.994075
Soggetto topico Nanomedicine
Cancer - Treatment - Technological innovations
Nanomedicina
Oncologia
Terapèutica
Soggetto genere / forma Llibres electrònics
ISBN 981-15-7564-9
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Intro -- Contents -- About the Editors -- 1: Nanoparticles for Cancer Therapy -- 1.1 Introduction -- 1.1.1 Cancer and its Types -- 1.1.2 Nanomedicine -- 1.2 Evolution of Cancer Therapy -- 1.2.1 Surgery and Adjuvant Therapies -- 1.2.2 Hormone Therapy -- 1.2.3 Immunotherapy -- 1.2.4 Cancer Therapy with Nanomedicine -- 1.3 Nanoparticles in Cancer Therapy -- 1.3.1 Protein Nanoparticles -- 1.3.2 Magnetic Nanoparticles -- 1.3.3 Inorganic Nanoparticles -- 1.3.4 Lipid Nanoparticles -- 1.3.5 Targeted Nanoparticles -- 1.3.6 Polymeric Nanoparticles -- 1.3.7 Multifunctional Nanoparticles -- 1.3.8 Quantum Dots -- 1.3.9 DNA Nanoparticles -- 1.4 Pharmacokinetics of Cancer Nanodrug Carriers -- 1.5 Cancer Nanomedical Research -- 1.5.1 Initial Advancements in Nanoparticle Research -- 1.5.2 Nanomedical Research Using Plant-Derived Compounds -- 1.5.3 Nanomedical Research Using Gene Therapeutic Strategies -- 1.5.4 Nanomedical Research Using In Vivo Imaging Techniques -- 1.5.5 Mainstream Research in the ``Golden Age´´ of Nanotechnology -- 1.5.6 Nanomedical Research Using Computational and Nanobioinformatic Tools -- 1.6 Nanomedicine in Cancer Diagnosis and Treatment -- 1.6.1 Immunoassays Using Nanomaterial-Embedded Microchips -- 1.6.2 In Vivo Imaging Using Nanoparticle Contrast Agents -- 1.6.3 Theranostic Nanomedicine -- 1.6.4 Cancer Nanodrug Release Systems and Personalized Cancer Nanomedicine -- 1.7 Current Research and Prospects -- 1.7.1 Smart Nanocarrier-Based Drug-Delivery Systems for Cancer Therapy -- 1.7.2 RNA Delivery Using Nanoparticles -- 1.7.3 Nanobots -- 1.8 Concluding Remarks -- References -- 2: Strategies for Improving the Efficiency of Nanomaterials -- 2.1 Introduction -- 2.2 Strategies for the Improvement of Nanomaterials -- 2.2.1 Photocatalytic Efficiency -- 2.2.2 Therapeutic Efficiency.
2.2.2.1 Strategic Improvement of Nanomaterials for Enhanced Permeability and Retention (EPR) Effects -- 2.2.2.2 Strategic Improvement of Nanomedicine for Improved Drug Delivery Systems -- Liposome Based Nanoformulation -- Nanoemulsions -- Solid Lipid Nanoparticles (SLN) -- Strategies for Organelles Specific Targeting of Nanodrugs -- Virus Based Nanoformulation -- 2.2.2.3 Photoactivated Nanomaterials for Photodynamic and Photothermal Therapy (PDT/PTT) -- 2.2.2.4 Mesoporous Silica Nanoparticles (MSNP) -- 2.2.2.5 Dendrimers -- 2.2.3 Engineering Nanoparticles to Evade the Multidrug Resistance (MDR) in Cancer -- 2.2.4 Nanoparticle-Based Combination Therapy -- 2.3 Conclusion -- References -- 3: Bioinspired Nanoparticles in Cancer Theranostics -- 3.1 Introduction -- 3.2 Novelty of Bioinspired Nanoparticles Based Theranostics -- 3.2.1 Liposomes in Cancer Theranostics -- 3.2.2 Lipid Nanoparticles in Cancer Theragnostic -- 3.2.2.1 Solid Lipid Nanoparticles (SLNs) -- 3.2.2.2 Nano-Structured Lipids (NLCs) -- 3.2.2.3 Lipid Nanocapsules (LNCs) -- 3.2.3 Protein-Based Nanoparticles for Cancer Theranostics -- 3.2.4 Virus like Nanoparticles in Cancer Theranostics -- 3.2.5 Inorganic and Bionanoparticles in Cancer Theranostics -- 3.3 Conclusions and Future Perspectives -- References -- 4: Nanomedicines for Solid Tumors: Current Status, Challenges, and Future Prospects -- 4.1 Introduction -- 4.2 Possible Factors that Initiate Cancer Growth -- 4.2.1 Age -- 4.2.2 Cancer Causing Elements -- 4.2.3 Immunosuppression -- 4.2.4 Infectious Agents -- 4.2.5 Radiation -- 4.3 Tumor Classification Based on Tissue of Origin -- 4.4 Existing Treatment Options Available for Cancer -- 4.5 Description of Solid Tumor -- 4.6 Nanomedicine -- 4.6.1 Unlocking Novel Cancer Applications Exploited in the Field of Nanomedicine -- 4.7 Fabrications of Nanocarrier for Drug Delivery.
4.8 Targeted Delivery of Nanocarrires to the Tumor Niche as Well as Solid Tumor -- 4.8.1 Drug Targeting Mechanisms and Surface Functionalization of Nanocarriers Aiding Nanomedicine Based Technologies in Solid ... -- 4.9 Nanoscience Based Imaging Technologies in the Detection of Solid Tumors -- 4.9.1 Photodynamic Nanomedicine in the Treatment of Solid Tumors -- 4.10 Nanomedicine and Solid Tumor Heterogenecity -- 4.11 Nanomedicine in Solid Tumors: PROS and CONS? -- 4.11.1 PROS -- 4.11.2 CONS -- 4.12 Discussion -- 4.13 Future Perspective -- References -- 5: Nanomaterials for Early Cancer Diagnostics -- 5.1 Introduction -- 5.2 Cancer and Biomarkers -- 5.2.1 Early Detection of Prostate Cancer -- 5.2.2 Early Detection of Breast Cancer -- 5.2.3 Early Detection of Lung Cancer -- 5.2.4 Early Detection of Liver Cancer -- 5.2.5 Early Detection of Oral Cancer -- 5.2.6 Early Detection of Pancreatic Cancer -- 5.2.7 Early Detection of Ovarian Cancer -- 5.2.8 Early Detection of Human Cervical Cancer -- 5.2.9 Early Detection of Bladder Cancer -- 5.2.10 Early Detection of Head and Neck Cancer -- 5.2.11 Early Detection of Colon Cancer -- 5.3 Conclusion -- References -- 6: Role of Nanomedicine for Cancer Immunotherapy -- 6.1 Introduction -- 6.2 Improving Cellular-Mediated Immunotherapy -- 6.2.1 Combining Therapeutic Agents to Immune Cells -- 6.2.2 Directing Therapeutic Drugs to Immune Cells -- 6.2.3 Delivery of Gene in Lymphocytes -- 6.3 Delivery Mechanism of Nanoparticle Therapeutics -- 6.3.1 Stimulating Immunogenic Cell Death (ICD) -- 6.3.1.1 Nanosized Drug Carriers -- 6.3.1.2 Nanopulse Stimulation -- 6.3.2 Enhanced Presentation of Ligands to Immune Cells -- 6.3.3 Chronological Regulation of Immunostimulation -- 6.4 Modulation in Pharmacokinetics of Immunotherapy Agents -- 6.5 Targeting Myeloid Cells -- 6.6 Targeting Stromal Cell in TME.
6.7 Limitations of Nanomedicines in Cancer Immunotherapy -- 6.8 Conclusion and Future Perspectives -- References -- 7: Targeting Tumor Microenvironment Through Nanotheranostics -- 7.1 Introduction -- 7.2 The Tumor Microenvironment (TME) and its Components -- 7.2.1 Cells of the Immune System -- 7.2.1.1 The T Cells -- 7.2.1.2 The B Cells -- 7.2.1.3 Tumor Associated Macrophages (TAMs) -- 7.2.1.4 Tumor Associated Neutrophils (TANs) -- 7.2.1.5 Natural Killer (NK) Cells -- 7.2.1.6 Cancer Associated Fibroblasts (CAFs) -- 7.2.2 The Extracellular Matrix (ECM) and Surrounding Cells -- 7.2.2.1 The Adipocytes -- 7.2.2.2 The Pericytes -- 7.2.2.3 Matrix Metalloproteases (MMPs) and Other Proteases -- 7.2.2.4 The Endothelial Cells -- 7.2.3 The TME, Inflammation, and Cancer -- 7.2.4 Hypoxia in the TME -- 7.3 The TME as an Attractive Therapeutic Target in Cancer -- 7.4 Cancer Nanotheranostic Agents that Target the TME -- 7.4.1 Metallic Nanoparticles (NPs) -- 7.4.2 Magnetic Nanoparticles (MNPs) -- 7.4.3 Mesoporous Silica Nanoparticles (MSiNPs) -- 7.4.4 Nano-Graphenes (NGs) -- 7.4.5 Polymeric-Based Nanotheranostic Particles (PNPs) -- 7.4.6 Lipid-Based Nanotheranostic Particles (LNPs) -- 7.4.7 Protein-Based Nanotheranostic Particles (PNPs) -- 7.4.8 Viral-Based Nanotheranostic Particles (VLPs) -- 7.4.9 DNA-Based Cancer Nanotheranostic Platform -- 7.5 Visualizing Cancer Through Nanotheranostics -- 7.5.1 Magnetic Resonance Imaging (MRI) -- 7.5.2 Photoacoustic Imaging (PAI) -- 7.5.3 Optical Imaging -- 7.5.4 Nuclear Imaging -- 7.6 Nanotheranostics for the Detection of Cancer Biomarkers -- 7.6.1 Labeling Nanoparticles with Conjugates -- 7.6.1.1 Chemical Crosslinking -- 7.6.1.2 Biotin/Avidin Conjugation -- 7.6.1.3 Click Chemistry -- 7.6.2 Target Moieties for Identification of Cancer Biomarkers -- 7.7 Conclusion and Future Direction -- References.
8: Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma -- 8.1 Introduction -- 8.1.1 Melanoma -- 8.1.1.1 Global Statistics and Market -- 8.1.1.2 Treatment Strategies -- 8.1.2 Nanotechnology in Melanoma -- 8.1.2.1 Nanoparticles for Melanoma -- 8.1.2.2 PAMAM -- 8.1.2.3 Zinc Oxide Nanoparticle -- 8.1.2.4 Titanium Dioxide Nanoparticle -- 8.1.2.5 Vanadium Pentoxide Nanoparticle -- 8.1.2.6 Copper Prussian Blue Nanoparticle -- 8.2 Importance of Noble Metal Nanoparticles in Biomedicine -- 8.3 Role of Noble Metals (Au, Ag, Pt) in Treatment of Melanoma -- 8.3.1 Gold (Au) Nanoparticles -- 8.3.1.1 Drug Delivery -- 8.3.1.2 Gene Delivery and Immunotherapy -- 8.3.1.3 Biosynthesized Gold Nanoparticles -- 8.3.1.4 Imaging -- 8.3.1.5 Photothermal and Photodynamic Therapy -- 8.3.2 Silver (Ag) Nanoparticles -- 8.3.3 Platinum (Pt) Nanoparticles -- 8.4 Toxicity of Noble Metal Nanoparticles -- 8.5 Challenges and Future Perspectives -- 8.6 Conclusion -- References -- 9: Ethics in Nanomedicine -- 9.1 Introduction -- 9.2 Nanomedicine -- 9.3 Difference Between Nanotechnology and Nanomedicine -- 9.4 Hype Versus Reality of Nanomedicine -- 9.5 Nondiscrimination and Integrity of Nanomedicine -- 9.6 The Potentiality of Nanomedicine -- 9.7 Biocompatibility and Toxicity of Nanostructures -- 9.8 Demand of the Nanomedicine in Market -- 9.9 Nanomedicine and Ethical Concerns -- 9.9.1 Ethical Problems Associated with Translational Research Involving Nanomedicine -- 9.9.2 Ethical Problems in Personalized and Regenerative Therapy with Nanomedicine -- 9.9.3 Ethical Concerns of Medical Surveillance -- 9.9.4 Ethical Challenges Inherent to Nanomedicine Applications -- 9.9.5 Social Ethics in Public Health Systems -- 9.9.5.1 Impact of Nanotechnology in Developing Nations -- 9.9.5.2 Impact of Nanotechnology on Laborers and Managerial Issues.
9.10 Future Perspectives.
Record Nr. UNINA-9910488707403321
Gateway East, Singapore : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Nanomedicine in Brain Diseases [[electronic resource] ] : Principles and Application / / edited by Xue Xue
Nanomedicine in Brain Diseases [[electronic resource] ] : Principles and Application / / edited by Xue Xue
Edizione [1st ed. 2019.]
Pubbl/distr/stampa Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019
Descrizione fisica 1 online resource (XIV, 313 p. 103 illus., 91 illus. in color.)
Disciplina 611.01816
Soggetto topico Molecular biology
Nanotechnology
Laboratory medicine
Molecular Medicine
Laboratory Medicine
Malalties cerebrals
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 981-13-8731-1
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Introduction: Nanomedicine in the Brain -- The Strategies of Nanomaterials for Traversing Blood-Brain Barrier -- The Strategies of Nanomaterials for Drug Delivery and Release -- The Strategies of Nanomaterials for Therapy -- The Strategies of Nanomaterials for Diagnostic and Imaging -- Nanoenzyme -- Biomacromolecule-Based Nanomedicine -- Carbon-Based Nanomedicine -- Polymeric Nanomedicine -- Magnetic Nanomedicine -- Boron Neutron Capture Nanomedicines.
Record Nr. UNINA-9910373919503321
Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Nanoparticles for rational vaccine design / / Harvinder Singh Gill, Richard W. Compans, editors
Nanoparticles for rational vaccine design / / Harvinder Singh Gill, Richard W. Compans, editors
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (140 pages)
Disciplina 615.372
Collana Current topics in microbiology and immunology
Soggetto topico Vaccines - Design
Vacunes
Immunoteràpia
Nanopartícules
Nanomedicina
Soggetto genere / forma Llibres electrònics
ISBN 3-030-85067-6
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910495172503321
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Nanotechnology applications in health and environmental sciences / / Necdet Saglam, Feza Korkusuz, Ram Prasad, editors
Nanotechnology applications in health and environmental sciences / / Necdet Saglam, Feza Korkusuz, Ram Prasad, editors
Edizione [1st ed. 2021.]
Pubbl/distr/stampa Cham, Switzerland : , : Springer, , [2021]
Descrizione fisica 1 online resource (XIV, 439 p. 77 illus., 62 illus. in color.)
Disciplina 610.28
Collana Nanotechnology in the Life Sciences
Soggetto topico Nanomedicine
Nanomedicina
Nanotecnologia
Medi ambient
Soggetto genere / forma Llibres electrònics
ISBN 3-030-64410-3
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Nota di contenuto Preface -- Diverse Manifolds of Biogenic Nanoparticles in Synthesis, Characterization and Applications -- Impact of Nanoparticles on Human Microbiota -- In-Vitro Applications of Nanoparticles -- Nanoparticles for Anticancer Drug Delivery -- Application of Nanotechnology in the Treatment of Microbial Infections -- Metal Organic Framework: Applications in Nanomedicine -- Recent Advances in Nanomaterial-Based Diagnosis and Treatment -- Nanobiosensors for Biomedical Applications -- Emerging Role of Nanomaterial Assisted Bio-Sensors for Circulating Tumor Cells Detection -- Advanced Functional Polymers for Biomedical Applications -- SERS Sensor Applications in Environmental Analysis and Biotechnology -- Design and Creation of Micro and Nano Environment in Regenerative and Restorative Medicine -- Presenting and Treating Bone Infections Using Silver-Ion Containing Nano-Hydroxyapatite -- Trace Element Containing Nano-HAp for Preventing Musculoskeletal Infections -- Biotechnological Approaches in Maintenance of a Healthy Immune System for Protection Against Diseases -- Production and Characterization of Antibiotic-Containing Nano-Calcium Phosphates -- Lantibiotics Nanotechnology, Bioengineering and Biotechnology -- Microbial Biotechnology and Postmortem Diagnosis -- Clean-Up and Pollution with Nanoparticles: An Environmental Dillemma -- Environmental Myco-Nanobiotechnology and Fungal Bioremediation -- Application of Nanotechnology in Detection and Diagnosis of Plant Diseases -- Index.
Record Nr. UNINA-9910484264003321
Cham, Switzerland : , : Springer, , [2021]
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Principles of nanomedicine [[electronic resource]]
Principles of nanomedicine [[electronic resource]]
Edizione [1st edition]
Pubbl/distr/stampa New York, : Jenny Stanford Publishing, 2019
Descrizione fisica 1 recurs en línia (606 pàgines)
Disciplina 610.28
Altri autori (Persone) BhattacharjeeSourav
Soggetto topico Nanomedicina
Nanomedicine
Soggetto genere / forma Llibres electrònics
ISBN 0-429-63205-3
0-429-03123-8
0-429-63354-8
Formato Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione eng
Record Nr. UNINA-9910793972703321
New York, : Jenny Stanford Publishing, 2019
Materiale a stampa
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui